Athenex Inc
F:2MT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Athenex Inc
Cost of Revenue
Athenex Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Athenex Inc
F:2MT
|
Cost of Revenue
-$76.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$17.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$9.7B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.9B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-17%
|
|
Athenex Inc
Glance View
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.
See Also
What is Athenex Inc's Cost of Revenue?
Cost of Revenue
-76.1m
USD
Based on the financial report for Dec 31, 2022, Athenex Inc's Cost of Revenue amounts to -76.1m USD.
What is Athenex Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-25%
Over the last year, the Cost of Revenue growth was -21%. The average annual Cost of Revenue growth rates for Athenex Inc have been -3% over the past three years , -25% over the past five years .
